This content is machine translated Small cell lung carcinoma Durvalumab approved as first immunotherapy for patients with LS-SCLC Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has...…
View Post 2 min This content is machine translated Small cell lung carcinoma Regulatory extension for durvalumab Durvalumab was approved EU-wide in combination with chemotherapy of etoposide plus either cisplatin or carboplatin followed by durvalumab maintenance therapy for the first-line treatment of adults with advanced-stage small cell…
